Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a clinical study titled SELECT-SLE: A Phase 3 Program to Evaluate the Safety and Efficacy of Upadacitinib in Subjects With Moderately to Severely Active SLE. The study aims to assess the safety and effectiveness of upadacitinib, a drug already approved for other conditions, in treating systemic lupus erythematosus (SLE). This research is significant as it could provide a new treatment option for SLE, a disease characterized by inflammation of multiple organ systems.
The intervention being tested is upadacitinib, an oral tablet, which is being compared to a placebo. The goal is to evaluate its impact on disease activity and adverse events in participants with moderate to severe SLE.
The study is designed as an interventional, randomized, and quadruple-masked trial. It follows a sequential intervention model with the primary purpose of treatment. This means participants, care providers, investigators, and outcomes assessors are unaware of who receives the drug or placebo, ensuring unbiased results.
The study began on July 19, 2023, with a primary completion date set for July 2025. The last update was submitted on July 21, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.
Market implications of this study are significant for AbbVie (ABBV), as positive results could enhance the company’s portfolio and potentially boost its stock performance. The study’s progress is also relevant in the context of competition within the pharmaceutical industry, where advancements in SLE treatment are highly anticipated.
The study is currently ongoing, with further details available on the ClinicalTrials portal.